All Stories

  1. Comparative effects of ayahuasca and breathwork on self-reported cognitive flexibility, emotion regulation, positive affect, and sleep quality
  2. Between Enhancement and Risk: A Critical Review of Psychedelic Microdosing
  3. Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper
  4. Safety and cognitive pharmacodynamics following dose escalations with 3-methylmethcathinone (3-MMC): a first in human, designer drug study
  5. Inter-individual variability in neural response to low doses of LSD
  6. Self-Rated Effectiveness of Ayahuasca and Breathwork on Well-Being, Psychological Resilience, Self-Compassion, and Personality: An Observational Comparison Study
  7. Effects of psychedelic microdosing versus conventional ADHD medication use on emotion regulation, empathy, and ADHD symptoms in adults with severe ADHD symptoms: A naturalistic prospective comparison study
  8. A Preliminary Inventory of Kratom (Mitragyna Speciosa) Products and Vendors on the Darknet and Cryptomarkets
  9. Assessment of the Acute Effects of 2C‐B vs. Psilocybin on Subjective Experience, Mood, and Cognition
  10. Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020
  11. Assessment of the acute effects of 2C-B vs psilocybin on subjective experience, mood and cognition
  12. Psilocybin induces acute and persisting alterations in immune status and the stress response in healthy volunteers
  13. Microdosing with psychedelics to self-medicate for ADHD symptoms in adults: A prospective naturalistic study
  14. A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans
  15. Spontaneous and deliberate creative cognition during and after psilocybin exposure
  16. Exploring the use of Kratom (Mitragyna speciosa) via the YouTube data tool: A novel netnographic analysis
  17. A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers
  18. Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin
  19. The therapeutic potential of microdosing psychedelics in depression
  20. Motives for Classical and Novel Psychoactive Substances Use in Psychedelic Polydrug Users
  21. Microdosing psychedelics: More questions than answers? An overview and suggestions for future research
  22. Psychedelic medicine: The biology underlying the persisting psychedelic effects
  23. Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being
  24. A First-in-Man Study with 4-Fluoroamphetamine Demonstrates it Produces a Mild Psychedelic State
  25. Increased Temporal Discounting in Social Anxiety Disorder Normalizes after Oxytocin Treatment
  26. Independent elevation of peripheral oxytocin concentrations and reduction in cognitive empathy during 4-fluoroamphetamine intoxication
  27. Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution
  28. Safety Profile and Neurocognitive Function Following Acute 4-Fluoroamphetamine (4-FA) Administration in Humans
  29. A single dose of cocaine enhances prospective memory performance
  30. Self-medication with psychedelics for mental or physical problems occurs amongst psychedelic users
  31. Intoxicated aggression: Do alcohol and stimulants cause dose-related aggression? A review
  32. Out of the box: A psychedelic model to study the creative mind
  33. Drug liking and wanting, not impulsive action or reflection is increased by 4-fluoroamphetamine
  34. Depressive mood ratings are reduced by MDMA in female polydrug ecstasy users homozygous for the l-allele of the serotonin transporter
  35. Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH‐018: a phase 1, placebo‐controlled, pilot study
  36. Peripheral endocannabinoid concentrations are not associated with verbal memory impairment during MDMA intoxication
  37. Emotional Empathic Responses to Dynamic Negative Affective Stimuli Is Gender-Dependent
  38. Erratum to: MDMA-induced indifference to negative sounds is mediated by the 5-HT2A receptor
  39. MDMA-induced indifference to negative sounds is mediated by the 5-HT2A receptor
  40. MDMA-Induced Dissociative State not Mediated by the 5-HT2A Receptor
  41. Multifaceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies
  42. A pooled analysis of on-the-road highway driving studies in actual traffic measuring standard deviation of lateral position (i.e., “weaving”) while driving at a blood alcohol concentration of 0.5 g/L
  43. Neurocognitive performance following acute mephedrone administration, with and without alcohol
  44. Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking
  45. Subjective aggression during alcohol and cannabis intoxication before and after aggression exposure
  46. Cannabis and tolerance: acute drug impairment as a function of cannabis use history
  47. Verbal Memory Impairment in Polydrug Ecstasy Users: A Clinical Perspective
  48. Brain reactivity to alcohol and cannabis marketing during sobriety and intoxication
  49. Cannabis and cocaine decrease cognitive impulse control and functional corticostriatal connectivity in drug users with low activity DBH genotypes
  50. Emotion recognition during cocaine intoxication
  51. MDMA, cannabis, and cocaine produce acute dissociative symptoms
  52. Psychedelic symptoms of cannabis and cocaine use as a function of trait impulsivity
  53. Changes in serotonin transporter (5-HTT) gene expression in peripheral blood cells after MDMA intake
  54. Memory and mood during MDMA intoxication, with and without memantine pretreatment
  55. Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans
  56. No Evidence that MDMA-Induced Enhancement of Emotional Empathy Is Related to Peripheral Oxytocin Levels or 5-HT1a Receptor Activation
  57. Single doses of THC and cocaine decrease proficiency of impulse control in heavy cannabis users
  58. Escitalopram Decreases Cross-Regional Functional Connectivity within the Default-Mode Network
  59. Methylphenidate reduces functional connectivity of nucleus accumbens in brain reward circuit
  60. Inhibition of MDMA-induced increase in cortisol does not prevent acute impairment of verbal memory
  61. Psychomotor Function in Chronic Daily Cannabis Smokers during Sustained Abstinence
  62. A Case-Control Study Estimating Accident Risk for Alcohol, Medicines and Illegal Drugs
  63. Medicinal Δ9-tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests
  64. Effects of Acute MDMA Intoxication on Mood and Impulsivity: Role of the 5-HT2 and 5-HT1 Receptors
  65. Effects of stimulant drugs on actual and simulated driving: perspectives from four experimental studies conducted as part of the DRUID research consortium
  66. A placebo-controlled study to assess Standardized Field Sobriety Tests performance during alcohol and cannabis intoxication in heavy cannabis users and accuracy of point of collection testing devices for detecting THC in oral fluid
  67. MDMA (ecstasy) effects on actual driving performance before and after sleep deprivation, as function of dose and concentration in blood and oral fluid
  68. MDMA intoxication and verbal memory performance: a placebo-controlled pharmaco-MRI study
  69. Blockade of 5-HT2 Receptor Selectively Prevents MDMA-Induced Verbal Memory Impairment
  70. Dose-related effects of MDMA on psychomotor function and mood before, during, and after a night of sleep loss
  71. Erratum: Involvement of Inferior Parietal Lobules in Prospective Memory Impairment During Acute MDMA (Ecstasy) Intoxication: An Event-Related fMRI Study
  72. Involvement of Inferior Parietal Lobules in Prospective Memory Impairment during Acute MDMA (Ecstasy) Intoxication: An Event-Related fMRI Study
  73. Memory and mood during the night and in the morning after repeated evening doses of MDMA
  74. Sustained attention and serotonin: a pharmaco-fMRI study
  75. Acute effects of nocturnal doses of MDMA on measures of impulsivity and psychomotor performance throughout the night
  76. The role of 5-HT1a and 5-HT2a receptors in attention and motor control: a mechanistic study in healthy volunteers
  77. Stimulant effects of 3,4-methylenedioxymethamphetamine (MDMA) 75 mg and methylphenidate 20 mg on actual driving during intoxication and withdrawal
  78. Selective verbal and spatial memory impairment after 5-HT1A and 5-HT2A receptor blockade in healthy volunteers pre-treated with an SSRI
  79. MDMA and alcohol effects, combined and alone, on objective and subjective measures of actual driving performance and psychomotor function
  80. Acute dose of MDMA (75 mg) impairs spatial memory for location but leaves contextual processing of visuospatial information unaffected
  81. Transient memory impairment after acute dose of 75mg 3.4-Methylene-dioxymethamphetamine
  82. A combined neurophysiological and behavioural study into the stimulating effects of fexofenadine on performance
  83. Acute Effects of 3,4-Methylenedioxymethamphetamine (MDMA) on Behavioral Measures of Impulsivity: Alone and in Combination with Alcohol